Description:

RTOG 1010 Follow-up Form (F1) Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=867B6E62-3E34-C9D2-E040-BB89AD4349E3

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=867B6E62-3E34-C9D2-E040-BB89AD4349E3
Keywords:
Versions (3)
  1. 8/26/12 8/26/12 -
  2. 1/9/15 1/9/15 - Martin Dugas
  3. 1/9/15 1/9/15 - Martin Dugas
Uploaded on:

January 9, 2015

DOI:
To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Adenocarcinoma of the Gastroesophageal Junction NCT01196390 Follow-Up - RTOG 1010 Follow-up Form (F1) - 3085847v1.0

English
Details

INSTRUCTIONS: Submit this form at the appropriate follow-up interval and whenever there is a change in the patient's status. Dates are recorded mm-dd-yyyy unless otherwise specified

1 forms  
Unnamed Module 1
Amended Data
Assessment
Vital Status
Primary Cause of Death
Has the patient had a documented clinical assessment for this cancer? (since submission of the previous follow-up form)
Current Disease Status
Primary Tumor
Regional lymph nodes
Distant metastasis
Second primary
Method of Evaluation
Events
Event
10 more items in the detailed view.
Performance Status
Unnamed2
Has a new primary cancer or MDS been diagnosed that has not been previously reported? (MYELODYSPLASTIC SYNDROME)
New Primary Site
15 more items in the detailed view.
Unnamed5
Non-Protocol Therapy Type
3 more items in the detailed view.
Toxicities
Grade 3 or 4 Restrictive Cardiomyopathy
Incipient CHF (Defined as asymptomatic >20% decrease in LVEF or a decrease of LVEF >10% below the institutions lower limit of normal who are judged to require treatment according to institutional guidelines)
Protocol Specific Adverse Event Evaluation
Any adverse events
CTC AE Grade
CTC AE Attribution Code
SAE report submitted
Footer Module
Back to the top of the page

Similar models

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial